Amy P N Skubitz
Overview
Explore the profile of Amy P N Skubitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boylan K, Walz C, Schefter A, Skubitz A
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075748
Background/objectives: New approaches to the treatment of women with ovarian cancer are desperately needed, since most women develop resistance to chemotherapy and the 5-year survival rate remains low. The hypothesis...
2.
Sah S, Schwiebert E, Moore S, Liu Y, Gaul D, Boylan K, et al.
Metabolites
. 2024 Nov;
14(11).
PMID: 39590836
: Ovarian cancer (OC) remains one of the most lethal cancers among women due to most cases going undiagnosed until later stages. The early detection and treatment of this malignancy...
3.
Do K, Mehta S, Wagner R, Bhuming D, Rajczewski A, Skubitz A, et al.
mSphere
. 2024 May;
9(6):e0079323.
PMID: 38780289
Importance: Clinical metaproteomics has immense potential to offer functional insights into the microbiome and its contributions to human disease. However, there are numerous challenges in the metaproteomic analysis of clinical...
4.
Ryu J, Boylan K, Twigg C, Evans R, Skubitz A, Thomas S
Clin Proteomics
. 2024 Jan;
21(1):1.
PMID: 38172678
Background: Ovarian cancer is the most lethal gynecologic malignancy in women, and high-grade serous ovarian cancer (HGSOC) is the most common subtype. Currently, no clinical test has been approved by...
5.
Do K, Mehta S, Wagner R, Bhuming D, Rajczewski A, Skubitz A, et al.
bioRxiv
. 2023 Dec;
PMID: 38045370
Clinical metaproteomics has the potential to offer insights into the host-microbiome interactions underlying diseases. However, the field faces challenges in characterizing microbial proteins found in clinical samples, which are usually...
6.
Boylan K, Petersen A, Starr T, Pu X, Geller M, Bast Jr R, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804849
Background: Individual serum biomarkers are neither adequately sensitive nor specific for use in screening the general population for ovarian cancer. The purpose of this study was to develop a multiprotein...
7.
Boylan K, Afiuni-Zadeh S, Geller M, Argenta P, Griffin T, Skubitz A
Clin Proteomics
. 2021 Jan;
18(1):4.
PMID: 33413078
Background: The purpose of this study was to determine whether the residual fixative from a liquid-based Pap test or a swab of the cervix contained proteins that were also found...
8.
Wesley E, Uppendahl L, Felices M, Dahl C, Messelt A, Boylan K, et al.
Gynecol Oncol
. 2020 Nov;
160(1):193-198.
PMID: 33168306
Objectives: Cytomegalovirus (CMV) is a common infection that establishes latency in healthy people. CMV has been associated with alterations of the immune compartment leading to improved responses, while inflammation has...
9.
Boylan K, Manion R, Shah H, Skubitz K, Skubitz A
Int J Mol Sci
. 2020 Jul;
21(13).
PMID: 32629816
The formation of 3D multicellular spheroids in the ascites fluid of ovarian cancer patients is an understudied component of the disease progression. Spheroids are less sensitive to chemotherapy, in part...
10.
Skubitz K, Wilson J, Cheng E, Lindgren B, Boylan K, Skubitz A
J Transl Med
. 2019 Apr;
17(1):130.
PMID: 30999901
Background: Cancer stem cells (CSC) may respond to chemotherapy differently from other tumor cells. Methods: This study examined the expression of the putative cancer stem cell markers ALDH1, CD44, and...